ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,114.63
-0.01%
Dow Jones
44,546.08
-0.37%
US Dollar vs MXN
20.32485
0.09%
Brent Oil
74.585
0.47%
Bitcoin
96,034.85
-0.10%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aptose Biosciences Inc (APTO)

  7. Aptose Biosciences Inc (APTO) Noticias

APTO

Aptose Biosciences (APTO)

Aptose Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:APTO
FechaHoraFuenteTítuloSímboloCompañía
14/02/202515:57Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APTOAptose Biosciences Inc
13/02/202519:26Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
13/02/202516:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APTOAptose Biosciences Inc
13/02/202516:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
13/02/202515:30GlobeNewswire Inc.Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityNASDAQ:APTOAptose Biosciences Inc
12/02/202506:00GlobeNewswire Inc.Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialNASDAQ:APTOAptose Biosciences Inc
03/02/202515:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APTOAptose Biosciences Inc
09/01/202515:00GlobeNewswire Inc.Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialNASDAQ:APTOAptose Biosciences Inc
19/12/202415:05GlobeNewswire Inc.Aptose Announces Positive Decision by Nasdaq Hearings PanelNASDAQ:APTOAptose Biosciences Inc
13/12/202416:03Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:APTOAptose Biosciences Inc
12/12/202409:15GlobeNewswire Inc.Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with VenetoclaxNASDAQ:APTOAptose Biosciences Inc
09/12/202411:00GlobeNewswire Inc.Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLNASDAQ:APTOAptose Biosciences Inc
03/12/202406:30GlobeNewswire Inc.Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsNASDAQ:APTOAptose Biosciences Inc
26/11/202417:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APTOAptose Biosciences Inc
25/11/202415:15GlobeNewswire Inc.Aptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
25/11/202405:05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APTOAptose Biosciences Inc
22/11/202407:00GlobeNewswire Inc.Aptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
21/11/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APTOAptose Biosciences Inc
20/11/202406:30GlobeNewswire Inc.Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNASDAQ:APTOAptose Biosciences Inc
14/11/202414:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
08/11/202415:01GlobeNewswire Inc.Aptose Reports Results for the Third Quarter 2024NASDAQ:APTOAptose Biosciences Inc
31/10/202405:39Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:APTOAptose Biosciences Inc
05/09/202415:15GlobeNewswire Inc.Aptose Announces Results from Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
30/08/202415:30GlobeNewswire Inc.Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibNASDAQ:APTOAptose Biosciences Inc
15/08/202415:30GlobeNewswire Inc.Aptose Announces Adjournment of its Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
08/08/202416:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APTOAptose Biosciences Inc
08/08/202416:06GlobeNewswire Inc.Aptose Reports Results for the Second Quarter 2024NASDAQ:APTOAptose Biosciences Inc
19/07/202416:00GlobeNewswire Inc.Aptose Announces Receipt of Deficiency Notice from NasdaqNASDAQ:APTOAptose Biosciences Inc
17/07/202410:43Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:APTOAptose Biosciences Inc
14/02/202415:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APTOAptose Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:APTO

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
COIN
SOLUSD
Solana
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
NASDAQ
GOOGL
Alphabet
COIN
ADAUSD
Cardano
COIN
ETHUSD
Ethereum
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
NYSE
KO
Coca Cola
CCOM
SILVER
SILVER
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios